What happened
Integra LifeSciences Holdings Corporation (NASDAQ: IART) lowered 2026 guidance after flooding at its Cincinnati facility hit third-quarter results. The company said third-quarter revenue should be about $410 million to $412 million, with adjusted earnings per diluted share of $0.55 to $0.59. It also expects operating cash flow to be greater than $85 million in the quarter.
The third-quarter figures are preliminary and still need financial closing procedures. Flood-related supply disruptions cut about $7 million from third-quarter revenue. The company expects another $15 million to $20 million hit in the fourth quarter. For the full year, Integra now expects reported revenue of $1.63 billion to $1.65 billion and adjusted EPS of $2.30 to $2.40.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Full-year 2026 reported revenue outlook | $1.63 billion to $1.65 billion | from $1.65 billion to $1.7 billion | Press release |
| Full-year 2026 adjusted EPS guidance | $2.30 to $2.40 | from $2.40 to $2.50 | Press release |
| Third-quarter 2026 revenue | $410 million to $412 million | SEC 8-K | |
| Third-quarter 2026 adjusted EPS | $0.55 to $0.59 | Press release | |
| Third-quarter 2026 operating cash flow | greater than $85 million | SEC 8-K | |
| Full-year 2026 operating cash flow | $190 million to $200 million | Press release |
Why it matters
OptimistFi's case is that the franchise can be monetized again if supply reliability normalizes, and this update is mixed for that view. The company said it continues to execute recovery plans, use available inventory and rely on alternate sources of supply for certain products. It also said product availability is improving, key products are returning to market and commercial execution is strengthening.
Management said the revised outlook reflects the July flooding event at the Cincinnati facility and updated assumptions for the rest of the year. The top end of full-year revenue guidance fell by $41 million, from $1.7 billion to $1.65 billion. The updated outlook still calls for operating cash flow of $190 million to $200 million in 2026. The caution is that the third-quarter figures are preliminary and unaudited, and the Cincinnati disruption is still expected to weigh on fourth-quarter revenue.
Browse: stock research on every company OptimistFi covers
What's next
In October 2026, Integra LifeSciences said it will report third-quarter 2026 financial results on a conference call, with a press release on the date, time and webcast to follow. The next operational milestone is the return to full manufacturing at Cincinnati in the second quarter of 2027.
A return on that schedule would support the recovery case by showing the flood is temporary. Any delay would keep pressure on revenue and cash generation. The conference call will be the next read on whether the recovery timeline and full-year outlook hold.
More from OptimistFi
- IART stock: the Integra LifeSciences thesis, its status and the next test to watch
- Fair Isaac Corporation (NYSE: FICO) Faces Equal Mortgage Pricing
- Broadcom Inc. (NASDAQ: AVGO) Has a $42 Billion Anthropic Test
- Autonomix Medical, Inc. (NASDAQ: AMIX) Gets a Clearer FDA Path
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- Press release — Press release attached as Exhibit 99.1 to the Form 8-K
- SEC 8-K — Current report announcing preliminary third-quarter results and updated guidance
Read the full OptimistFi thesis on Integra LifeSciences Holdings Corporation: https://optimistfi.com/stocks/IART
See what would break the Integra LifeSciences Holdings Corporation thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Integra LifeSciences Holdings Corporation investment case, its status and the next test to watch live on the Integra LifeSciences Holdings Corporation thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
